← Back to Search

Monoclonal Antibodies

ZW191 for Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by Zymeworks BC Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Pathologically or cytologically confirmed diagnosis of cancers with evidence of locally advanced (unresectable), recurrent and/or metastatic disease.
* Measurable disease per RECIST v1.1.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 2 years
Awards & highlights

Summary

The purpose of this study is to find out if ZW191 is safe and can treat participants with advanced cancers, including ovarian, endometrial, and non-small cell lung cancers.

Eligible Conditions
  • Solid Tumors

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Confirmed objective response rate (Part 2)
Incidence of adverse events (AEs; Parts 1 and 2)
Incidence of clinical laboratory abnormalities (Parts 1 and 2)
+1 more
Secondary study objectives
Best overall response (BOR; Part 2)
Clinical benefit rate (Parts 1 and 2)
Confirmed objective response rate (Part 1)
+5 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: ZW191Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Zymeworks BC Inc.Lead Sponsor
5 Previous Clinical Trials
1,171 Total Patients Enrolled
Josemund Menezes, MBBS, BCMASStudy DirectorZymeworks BC Inc.
~97 spots leftby Dec 2026